Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Pleasant Surprise For InterMune With Early Positive Opinion On Pirfenidone From CHMP

This article was originally published in The Pink Sheet Daily

Executive Summary

With approval in EU nearly certain for IPF drug, InterMune's share price more than doubles.

You may also be interested in...



Biogen Idec Buys Stromedix, Bringing IPF Candidate Full Circle

Started by a former Biogen executive, Stromedix licensed STX-100 from Biogen and developed it into an attractive candidate in an area the reshaped big biotech wants to pursue.

InterMune Gets Ready To Go Commercial With Esbriet Launch In Europe

InterMune plans to launch the first drug for IPF in Europe in September, and has initiated a new Phase III trial with the aim of securing U.S. approval in 2014.

InterMune Gets Ready To Go Commercial With Esbriet Launch In Europe

InterMune plans to launch the first drug for IPF in Europe in September, and has initiated a new Phase III trial with the aim of securing U.S. approval in 2014.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS071629

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel